Mizagliflozin is an SGLT1 inhibitor developed as a potential treatment for chronic constipation. It progressed as far as Phase II trials in humans but was not approved for medical use, however it has since been investigated for other applications.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.